#USA #Fremont #Clinical Research #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Unveils NULISAqpcr™ Custom Assay Development Kit

A Leap Forward in Biomarker Testing

On February 24, 2025, Alamar Biosciences, renowned for its innovative approach in precision proteomics, proudly announced the launch of the NULISAqpcr™ Custom Assay Development Kit. This groundbreaking product is designed to empower researchers in developing highly sensitive and precise biomarker tests tailored to their specific research needs. The introduction of this kit significantly expands the application of Alamar's NULISA™ technology, making it a valuable asset for the broader biomarker research community.

Enhanced Flexibility for Researchers

The NULISAqpcr Custom Assay Development Kit stands out for its unrivaled flexibility, enabling scientists to leverage their antibodies to create targeted assays with exceptional sensitivity and reproducibility. This kit is particularly suited for disciplines requiring high sensitivity and a broad dynamic range, such as immunology and neurology. With its customizable workflow moving seamlessly from antibody conjugation to automated NULISAqpcr steps using the ARGO™ HT system, it sets a new benchmark for the development of proprietary single-layer tests.

Yuling Luo, Ph.D., founder, chairman, and CEO of Alamar Biosciences, remarked, "The Custom Assay Development Kit directly addresses the increasing demand from researchers who wish to harness our cutting-edge NULISA technology to develop high-performance biomarker tests for translational and clinical research. This product launch represents a significant milestone in our mission to build a transformative ecosystem that supports precision proteomics."

Commitment to Innovation and Research Support

By unveiling the NULISAqpcr Custom Assay Development Kit, Alamar continues to solidify its commitment to leading innovation and supporting the scientific community with advanced solutions. The kit will be available for order, with shipments expected to commence in the second quarter of 2025.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private life sciences firm dedicated to promoting precision proteomics, enabling the earliest possible disease detection. Its proprietary NULISA™ platform, alongside the ARGO™ HT system, integrates the latest advancements in genomics, achieving attomolar sensitivity—outpacing the most sensitive protein detection technologies available today. With a mission to bolster research, Alamar is poised to redefine biomarker detection standards. For more information, visit alamarbio.com.

Conclusion

The introduction of the NULISAqpcr Custom Assay Development Kit not only exemplifies Alamar's dedication to improving clinical research methodologies but also highlights the company's ongoing efforts to foster innovation within the biomarker testing arena. As the demand for precision in clinical investigations rises, tools like these become crucial in enabling breakthroughs in early disease detection and treatment strategies.